by Plus Therapeutics | Feb 28, 2026 | LM
Today, Plus Therapeutics joins the global community in recognizing Rare Disease Day, an annual moment dedicated to raising awareness and advancing efforts for the more than 300 million people worldwide living with a rare disease. Rare Disease Day serves as a powerful...
by Plus Therapeutics | Jan 12, 2026 | LM
Plus Therapeutics is proud to collaborate with CNSide Diagnostics and the Leptomeningeal Cancer Foundation on the development of a new educational resource designed to support individuals affected by leptomeningeal metastases (LM), as well as their caregivers and...
by Plus Therapeutics | Jan 8, 2026 | LM
Plus Therapeutics is pleased to announce the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss next steps in the clinical development of REYOBIQ™ for the treatment of leptomeningeal metastases (LM). This meeting...
by Plus Therapeutics | Dec 18, 2025 | LM
Expert Insights: Dr. Andrew Brenner on the Path Forward In a recent video interview with Sabrina McCrear of AJMC – The American Journal of Managed Care, Andrew Brenner, MD, PhD, provided a deeper look into the significance of the SABCS presentations. Dr. Brenner...
by Plus Therapeutics | Dec 15, 2025 | LM
At the 2025 San Antonio Breast Cancer Symposium (SABCS), Plus Therapeutics and its clinical partners shared important progress in the fight against leptomeningeal metastases (LM) with the presentation of Phase 1 dose escalation results from the ReSPECT-LM clinical...
by Plus Therapeutics | Dec 1, 2025 | LM
Plus Therapeutics is pleased to announce that its abstract has been accepted for a Poster Spotlight with Oral Presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025), taking place December 9–12, 2025, in San Antonio, Texas. This recognition...
Recent Comments